NCT05126290Recruiting
CTNNA1 Familial Expansion Study
CTNNA1 Familial Expansion (CAFÉ) Study
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 2 Nov 2021
- Start date
- 16 Mar 2021
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05126290
What you commit to
- Study type: Observational
- Planned participants: 100
- From 16 Mar 2021 to the primary completion date, 1 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Major psychiatric illness or cognitive impairment that in the judgement of the study investigators or study staff would preclude study participation
Age
- Less than 18 years of age
Other
- Individuals who do not carry a CTNNA1 loss-of-function variant and are not a first degree relative of a CTNNA1 loss-of-function variant carrier.
- Individuals who cannot speak and read English
- Unable to comply with the study procedures as determined by the study investigators or study staff
Who the study is looking for
- 18 years of age and older
- Participants must be carrier, or a first degree relative of a carrier, of a CTNNA1 loss-of-function variant defined as: a variant predicted to lead to protein truncation (nonsense and frameshift variants), a large deletion of one or more exons, or a consensus splice site variant predicted to disrupt splicing in CTNNA1. CTNNA1 loss-of-function variants do not need to be classified as pathogenic or likely pathogenic to be included.
- Participants must be able to understand and read English
- Participants must be able to provide informed verbal or written consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Abramson Cancer Center of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.